vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是Resolute Holdings Management, Inc.的1.3倍（$152.6M vs $117.7M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -1.5%，领先36.0%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $44.9M）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
CPRX vs RHLD — 直观对比
营收规模更大
CPRX
是对方的1.3倍
$117.7M
净利率更高
CPRX
高出36.0%
-1.5%
自由现金流更多
RHLD
多$144.4M
$44.9M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $117.7M |
| 净利润 | $52.7M | $-1.7M |
| 毛利率 | 82.9% | 55.7% |
| 营业利润率 | 40.5% | 30.2% |
| 净利率 | 34.5% | -1.5% |
| 营收同比 | 7.6% | — |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXRHLD
| Q4 25 | $152.6M | $117.7M | ||
| Q3 25 | $148.4M | $120.9M | ||
| Q2 25 | $146.6M | $119.6M | ||
| Q1 25 | $141.4M | $103.9M | ||
| Q4 24 | $141.8M | — | ||
| Q3 24 | $128.7M | — | ||
| Q2 24 | $122.7M | — | ||
| Q1 24 | $98.5M | — |
净利润CPRXRHLD
| Q4 25 | $52.7M | $-1.7M | ||
| Q3 25 | $52.8M | $-231.0K | ||
| Q2 25 | $52.1M | $-611.0K | ||
| Q1 25 | $56.7M | $-3.4M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | — | ||
| Q2 24 | $40.8M | — | ||
| Q1 24 | $23.3M | — |
毛利率CPRXRHLD
| Q4 25 | 82.9% | 55.7% | ||
| Q3 25 | 84.7% | 59.0% | ||
| Q2 25 | 85.9% | 57.5% | ||
| Q1 25 | 87.3% | 52.5% | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
营业利润率CPRXRHLD
| Q4 25 | 40.5% | 30.2% | ||
| Q3 25 | 44.7% | 34.3% | ||
| Q2 25 | 45.2% | 34.0% | ||
| Q1 25 | 44.8% | 24.7% | ||
| Q4 24 | 44.3% | — | ||
| Q3 24 | 39.6% | — | ||
| Q2 24 | 44.2% | — | ||
| Q1 24 | 27.5% | — |
净利率CPRXRHLD
| Q4 25 | 34.5% | -1.5% | ||
| Q3 25 | 35.6% | -0.2% | ||
| Q2 25 | 35.6% | -0.5% | ||
| Q1 25 | 40.1% | -3.2% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | — | ||
| Q2 24 | 33.2% | — | ||
| Q1 24 | 23.6% | — |
每股收益（稀释后）CPRXRHLD
| Q4 25 | $0.40 | $-0.20 | ||
| Q3 25 | $0.42 | $-0.03 | ||
| Q2 25 | $0.41 | $-0.07 | ||
| Q1 25 | $0.45 | $-0.39 | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.35 | — | ||
| Q2 24 | $0.33 | — | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $954.3M | $6.5M |
| 总资产 | $1.1B | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资CPRXRHLD
| Q4 25 | $709.2M | $205.5M | ||
| Q3 25 | $689.9M | $148.0M | ||
| Q2 25 | $652.8M | $99.9M | ||
| Q1 25 | $580.7M | $71.0M | ||
| Q4 24 | $517.6M | — | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | — | ||
| Q1 24 | $310.4M | — |
总债务CPRXRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CPRXRHLD
| Q4 25 | $954.3M | $6.5M | ||
| Q3 25 | $920.2M | $10.8M | ||
| Q2 25 | $856.0M | $9.6M | ||
| Q1 25 | $794.3M | $8.9M | ||
| Q4 24 | $727.6M | — | ||
| Q3 24 | $660.9M | — | ||
| Q2 24 | $608.7M | — | ||
| Q1 24 | $561.4M | — |
总资产CPRXRHLD
| Q4 25 | $1.1B | $333.4M | ||
| Q3 25 | $1.1B | $293.2M | ||
| Q2 25 | $971.9M | $253.3M | ||
| Q1 25 | $908.9M | $214.3M | ||
| Q4 24 | $851.4M | — | ||
| Q3 24 | $772.0M | — | ||
| Q2 24 | $706.4M | — | ||
| Q1 24 | $646.7M | — |
负债/权益比CPRXRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $189.2M |
| 自由现金流率自由现金流/营收 | 29.4% | 160.8% |
| 资本支出强度资本支出/营收 | 0.0% | 5.8% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $313.2M |
8季度趋势，按日历期对齐
经营现金流CPRXRHLD
| Q4 25 | $44.9M | $196.1M | ||
| Q3 25 | $32.4M | $59.6M | ||
| Q2 25 | $71.3M | $48.9M | ||
| Q1 25 | $60.0M | $18.4M | ||
| Q4 24 | $70.9M | — | ||
| Q3 24 | $72.9M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.9M | — |
自由现金流CPRXRHLD
| Q4 25 | $44.9M | $189.2M | ||
| Q3 25 | — | $58.6M | ||
| Q2 25 | $71.3M | $47.5M | ||
| Q1 25 | — | $17.8M | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
自由现金流率CPRXRHLD
| Q4 25 | 29.4% | 160.8% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | 48.6% | 39.7% | ||
| Q1 25 | — | 17.1% | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度CPRXRHLD
| Q4 25 | 0.0% | 5.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率CPRXRHLD
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RHLD
暂无分部数据
